Frontlight ResearchEarly access
Taking peopleNo phase
Multicentric Clinical Investigation to Assess Safety and Performance of Lux HighAdd IOL
Key facts
- Who runs it
- Cutting Edge SAS
- Where
- France3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 57 people, planned
- Started
- 19 Dec 2024
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- LuxHighAdd IOL
- LuxGood IOL
- Record updated
- 26 May 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Subject aged 50 or over on the day of inclusion, presenting a bilateral cataract, qualified for bilateral implantation
- No ocular comorbidity possibly affecting the study results
- Fit within the available IOL diopter range
- Have had no previous refractive surgery
- Regular corneal astigmatism ≤1.0 dioptres
- Clear intraocular media other than cataract
- Availability, willingness and sufficient cognitive awareness to comply with examination procedures
- Ability to attend all study follow-ups
- Signed informed consent
Who cannot take part
- Subjects who may be reasonably expected to require a secondary surgical intervention at any time during the investigation (other than YAG capsulotomy)
- History of ocular trauma or any prior ocular surgery including refractive procedures
- Systemic or ocular medication that could modify pupil dynamics
- Expected complicated surgery or complicated surgery
- Concurrent participation in another drug or device investigation
- Ocular surface disease potentially affecting study results
- Pre-existing ocular pathology or history of pathology potentially affecting the study results
- Acute or chronic disease or illness that would increase risk or confound study results
- Axial lengths and keratometry such as the IOL spherical power is not in the range of 16 to 26 D
- Instability of keratometry or biometry measurements
- Traumatic cataract
- Amblyopia
- Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens
- Pupil abnormalities
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study purpose is to demonstrate safety and performance of bilateral implantation of LuxHighAdd intraocular lens compared with the LuxGood Monofocal lens.
The 2 groups in the trial
- LuxHighAddTreatment being tested
The experimental group will recieve the LuxHighAdd intraocular lens bilaterally.
Treatment: LuxHighAdd IOL
- LuxGood groupExisting treatment, for comparison
The control group will recieve the LuxGood intraocular lens bilaterally.
Treatment: LuxGood IOL
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicentric Clinical Investigation to Determine Safety and Efficacy of a Hydrophobic Acrylic Multifocal Intraocular Lens
- Record updated
- 26 May 2026